BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15755960)

  • 1. Chemoprevention in the 21st century: is a balance best or should women have no estrogen at all?
    Jordan VC
    J Clin Oncol; 2005 Mar; 23(8):1598-600. PubMed ID: 15755960
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in adjuvant hormonal therapy for postmenopausal women.
    Strasser-Weippl K; Goss PE
    J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
    [No Abstract]   [Full Text] [Related]  

  • 3. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC
    Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
    Kendall A; Dowsett M
    Endocr Relat Cancer; 2006 Sep; 13(3):827-37. PubMed ID: 16954432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal therapy for advanced breast cancer.
    Rugo HS
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors for breast cancer prevention.
    Cuzick J
    J Clin Oncol; 2005 Mar; 23(8):1636-43. PubMed ID: 15755971
    [No Abstract]   [Full Text] [Related]  

  • 8. Estrogen-receptor biology: continuing progress and therapeutic implications.
    Osborne CK; Schiff R
    J Clin Oncol; 2005 Mar; 23(8):1616-22. PubMed ID: 15755967
    [No Abstract]   [Full Text] [Related]  

  • 9. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
    Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
    Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of breast cancer.
    Castrellon AB; Glück S
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy for breast cancer: an overview.
    Cheung KL
    Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alphabet soup of chemotherapy.
    Dinman S
    Plast Surg Nurs; 2007; 27(3):173-5. PubMed ID: 17901830
    [No Abstract]   [Full Text] [Related]  

  • 13. Aromatase inhibitors: a time for reflection.
    Birge SJ
    Menopause; 2007; 14(6):971-2. PubMed ID: 17975522
    [No Abstract]   [Full Text] [Related]  

  • 14. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
    Dunn BK; Ryan A
    Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
    Altundag K; Kurt M; Islam R; Altundag O; Turen S
    Med Hypotheses; 2006; 66(2):444-5. PubMed ID: 15996830
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer prevention.
    Euhus DM; Diaz J
    Breast J; 2015; 21(1):76-81. PubMed ID: 25413630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SERMs: meeting the promise of multifunctional medicines.
    Jordan VC
    J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agents in development for breast cancer.
    Gao XP; Liu F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of breast cancer among women at elevated risk as defined by Gail Score.
    Micallef S; Micallef D; Schembri-Wismayer P; Brincat MP; Calleja-Agius J
    Minerva Ginecol; 2015 Aug; 67(4):335-52. PubMed ID: 25668503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.